Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1573-7322
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Sodium-glucose cotransporter 2 inhibitors and heart failure: the best timing for the right patient ; day:16 ; month:10 ; year:2021 ; pages:1-13
Heart failure reviews ; (16.10.2021), 1-13

Urheber
Severino, Paolo
D’Amato, Andrea
Prosperi, Silvia
Costi, Bettina
Angotti, Danilo
Birtolo, Lucia Ilaria
Chimenti, Cristina
Lavalle, Carlo
Maestrini, Viviana
Mancone, Massimo
Fedele, Francesco
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s10741-021-10170-1
URN
urn:nbn:de:101:1-2021123018111618781792
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:21 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Severino, Paolo
  • D’Amato, Andrea
  • Prosperi, Silvia
  • Costi, Bettina
  • Angotti, Danilo
  • Birtolo, Lucia Ilaria
  • Chimenti, Cristina
  • Lavalle, Carlo
  • Maestrini, Viviana
  • Mancone, Massimo
  • Fedele, Francesco
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-glucose cotransporter 2 inhibition prevents renal fibrosis in cyclosporine nephropathy

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and Cardiovascular Disease: A Systematic Review

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions : state of the art

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

COVID-19 and Sodium-Glucose Cotransporter 2 Inhibitors: No Fear to Attempt?

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Sodium-glucose cotransporter 2 inhibitors in cardiology: Slow start and sweet passage

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Redox-driven cardioprotective effects of sodium-glucose co-transporter-2 inhibitors: comparative review

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report

Severe intoxication caused by sodium-glucose cotransporter 2 inhibitor overdose: a case report

Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors

Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors

Verbundene Objekte